SPYPBO-101 is listed as a product in 2 authorised or ongoing trials in the EU clinical trials register (CTIS). All registered phases are Phase 2. The sponsor is Spyre Therapeutics Inc. It does not appear under this name in the ClinicalTrials.gov records behind our other registers.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product named SPYPBO-101. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease
2025-524640-35-00 · CTIS ↗ · Digestive System Diseases
|
Phase 2 | Ongoing | Spyre Therapeutics Inc | Croatia, Poland, Austria + 12 more |
|
Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis
2025-521242-26-00 · CTIS ↗ · Digestive System Diseases
|
Phase 2 | Ongoing | Spyre Therapeutics Inc | Belgium, Hungary, Lithuania + 13 more |
| Lead sponsor | Trials |
|---|---|
| Spyre Therapeutics Inc | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| EU register (CTIS) | 2 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
2 authorised or ongoing trials in the EU clinical trials register (CTIS) list a product named SPYPBO-101, as of the registry sync on 26 September 2026. It is not named in the ClinicalTrials.gov records behind our Ireland, UK, USA, India and China registers.
The lead sponsor is Spyre Therapeutics Inc. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public EU CTIS records by a daily sync. Nothing here describes how SPYPBO-101 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how SPYPBO-101 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists SPYPBO-101 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.